{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:06:39Z","timestamp":1774641999817,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An increasing number of individuals who use drugs in North America are preferentially consuming fentanyl over other opioids. This has significant consequences on the treatment and management of opioid use disorder (OUD) and its concurrent disorders, especially in acute care if opioid requirements are not met.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present a patient with severe OUD and daily injection of fentanyl, admitted to hospital for management of acute physical health issues. Due to high opioid requirements and history of patient-initiated discharge, intravenous fentanyl was administered for treatment of opioid withdrawal, and management of pain, which supported continued hospitalization for acute care treatment and aligned with substance use treatment goals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case demonstrates that intravenous fentanyl for management of OUD in hospital can be a feasible approach to meet opioid requirements and avoid fentanyl withdrawal among patients with severe OUD and daily fentanyl use, thereby promoting adherence to medical treatment and reducing the risk of patient-initiated discharge. There is an urgent need to tailor current treatment strategies for individuals who primarily use fentanyl. Carefully designed research is needed to further explore the use of IV fentanyl for acute care management of severe opioid withdrawal in a hospital setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00305-6","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:09:51Z","timestamp":1649153391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: acute care management of severe opioid withdrawal with IV fentanyl"],"prefix":"10.1186","volume":"17","author":[{"given":"Pouya","family":"Azar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-8402","authenticated-orcid":false,"given":"Jean N.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha J.","family":"Ignaszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Isac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickie","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"4","key":"305_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","volume":"34","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021;34(4):405\u201312.","journal-title":"Curr Opin Psychiatry"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107\u201311.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"305_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13033-021-00512-9","volume":"15","author":"M Krausz","year":"2021","unstructured":"Krausz M, Westenberg JN, Mathew N, Budd G, Wong JSH, Tsang VWL, et al. Shifting North American drug markets and challenges for the system of care. Int J Ment Health Syst. 2021;15(1):86.","journal-title":"Int J Ment Health Syst."},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","volume":"171","author":"J Suzuki","year":"2017","unstructured":"Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","volume":"46","author":"JJ Carroll","year":"2017","unstructured":"Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. Int J Drug Policy. 2017;46:136\u201345.","journal-title":"Int J Drug Policy"},{"issue":"107547","key":"305_CR6","first-page":"1","volume":"204","author":"KB Morales","year":"2019","unstructured":"Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019;204(107547):1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"305_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ajad.13092","volume":"30","author":"S Martinez","year":"2021","unstructured":"Martinez S, Jones JD, Brandt L, Campbell ANC, Abbott R, Comer SD. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. Am J Addict. 2021;30(1):65\u201371.","journal-title":"Am J Addict"},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"103574","DOI":"10.1016\/j.drugpo.2021.103574","volume":"101","author":"M Ferguson","year":"2022","unstructured":"Ferguson M, Parmar A, Papamihali K, Weng A, Lock K, Buxton JA. Investigating opioid preference to inform safe supply services: a cross sectional study. Int J Drug Policy. 2022;101:103574.","journal-title":"Int J Drug Policy"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/add.15376","volume":"116","author":"ASB Bohnert","year":"2021","unstructured":"Bohnert ASB, Lin LA. It is time to recognize that synthetic opioids are not going away. Addiction. 2021;116:1313\u20138.","journal-title":"Addiction"},{"key":"305_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.8114","author":"NP Morris","year":"2022","unstructured":"Morris NP. Opioid use disorder treatment in the age of fentanyl. JAMA Intern Med. 2022. https:\/\/doi.org\/10.1001\/jamainternmed.2021.8114.","journal-title":"JAMA Intern Med"},{"key":"305_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.8111","author":"AP Thakrar","year":"2022","unstructured":"Thakrar AP. Short-acting opioids for hospitalized patients with opioid use disorder. JAMA Intern Med. 2022. https:\/\/doi.org\/10.1001\/jamainternmed.2021.8111.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"305_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40429-019-00267-x","volume":"6","author":"M Weimer","year":"2019","unstructured":"Weimer M, Morford K, Donroe J. Treatment of opioid use disorder in the acute hospital setting: a critical review of the literature (2014\u20132019). Curr Addict Rep. 2019;6(4):339\u201354.","journal-title":"Curr Addict Rep"},{"issue":"2","key":"305_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ADM.0000000000000725","volume":"15","author":"NS Nolan","year":"2021","unstructured":"Nolan NS, Marks LR, Liang SY, Durkin MJ. Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection. J Addict Med. 2021;15(2):155\u20138.","journal-title":"J Addict Med"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. \u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"305_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/ADM.0000000000000499","volume":"13","author":"JL Moreno","year":"2019","unstructured":"Moreno JL, Wakeman SE, Duprey MS, Roberts RJ, Jacobson JS, Devlin JW. Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder. J Addict Med. 2019;13(4):306\u201313.","journal-title":"J Addict Med"},{"issue":"1","key":"305_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-018-0274-2","volume":"16","author":"SC Carusone","year":"2019","unstructured":"Carusone SC, Guta A, Robinson S, Tan DH, Cooper C, O\u2019Leary B, et al. \u201cMaybe if I stop the drugs, then maybe they\u2019d care?\u201d\u2014hospital care experiences of people who use drugs. Harm Reduct J. 2019;16(1):1\u201310.","journal-title":"Harm Reduct J"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsat.2020.01.010","volume":"112","author":"E Merchant","year":"2020","unstructured":"Merchant E, Burke D, Shaw L, Tookes H, Patil D, Barocas JA, et al. Hospitalization outcomes of people who use drugs: one size does not fit all. J Subst Abuse Treat. 2020;112:23\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"305_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13722-021-00234-w","volume":"16","author":"L Mackay","year":"2021","unstructured":"Mackay L, Kerr T, Fairbairn N, Grant C, Milloy M-J, Hayashi K. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting. Addict Sci Clin Pract. 2021;16(1):26.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"305_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13011-019-0241-2","volume":"14","author":"G Bardwell","year":"2019","unstructured":"Bardwell G, Wood E, Brar R. Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Subst Abuse Treat Prev Policy. 2019;14(1):50. https:\/\/doi.org\/10.1186\/s13011-019-0241-2.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"305_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2215-0366(21)00393-X","volume":"9","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment? Lancet Psychiatry. 2021;9(2):103\u20135.","journal-title":"Lancet Psychiatry"},{"issue":"10324","key":"305_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","volume":"399","author":"K Humphreys","year":"2022","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(21)02252-2.","journal-title":"Lancet"},{"key":"305_CR22","unstructured":"British Columbia Centre on Substance Use (BCCSU) and British Columbia Ministry of Health. Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver, BC; 2021. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2021\/07\/BC_iOAT_Guideline.pdf"},{"issue":"38","key":"305_CR23","doi-asserted-by":"publisher","first-page":"E1049","DOI":"10.1503\/cmaj.190344","volume":"191","author":"N Fairbairn","year":"2019","unstructured":"Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. Can Med Assoc J. 2019;191(38):E1049\u201356.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"305_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00358-x","volume":"16","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1):1\u20137.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"305_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/dar.13020","volume":"39","author":"M McAdam","year":"2020","unstructured":"McAdam M, Brar R, Young S. Initiation of injectable opioid agonist treatment in hospital: a case report. Drug Alcohol Rev. 2020;39(2):138\u201341.","journal-title":"Drug Alcohol Rev"},{"issue":"8","key":"305_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"issue":"5","key":"305_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiat. 2016;73(5):447\u201355.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"305_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"305_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Br J Psychiatry. 2007;191(1):55\u201362.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"305_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jsat.2010.03.003","volume":"38","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010;38(4):408\u201311.","journal-title":"J Subst Abuse Treat"},{"key":"305_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2039814","author":"P Azar","year":"2022","unstructured":"Azar P, Mathew N, Mahal D, Wong JSH, Westenberg JN, Schutz C. Developing a rapid transfer from opioid full agonist to buprenorphine: \u2018Ultrarapid Micro-Dosing\u2019\u2019 proof of concept\u2019. J Psychoactive Drugs. 2022. https:\/\/doi.org\/10.1080\/02791072.2022.2039814.","journal-title":"J Psychoactive Drugs"},{"issue":"22","key":"305_CR32","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1001\/jama.289.22.2983","volume":"289","author":"EW Ely","year":"2003","unstructured":"Ely EW, Truman B, Shintani A, Thomason JWW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983\u201391.","journal-title":"JAMA"},{"issue":"4","key":"305_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11414-020-09710-8","volume":"47","author":"G Neimark","year":"2020","unstructured":"Neimark G, Tjoa C. Treating fentanyl withdrawal. J Behav Health Serv Res. 2020;47(4):614\u20135.","journal-title":"J Behav Health Serv Res"},{"issue":"8","key":"305_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/ajad.12809","volume":"27","author":"P Azar","year":"2018","unstructured":"Azar P, Nikoo M, Miles I. Methadone to buprenorphine\/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting\u2014Azar method. Am J Addict. 2018;27(8):601\u20134.","journal-title":"Am J Addict"},{"issue":"4","key":"305_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajad.12869","volume":"28","author":"S Klaire","year":"2019","unstructured":"Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262\u20135.","journal-title":"Am J Addict"},{"issue":"1","key":"305_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-021-00220-2","volume":"16","author":"JSH Wong","year":"2021","unstructured":"Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, et al. Comparing rapid micro-induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021;16(1):11. https:\/\/doi.org\/10.1186\/s13722-021-00220-2.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"305_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7. https:\/\/doi.org\/10.1186\/s13011-020-0253-y.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"305_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1359-1789(01)00057-X","volume":"8","author":"SM Boles","year":"2003","unstructured":"Boles SM, Miotto K. Substance abuse and violence: a review of the literature. Aggress Violent Behav. 2003;8(2):155\u201374.","journal-title":"Aggress Violent Behav"},{"issue":"1","key":"305_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","volume":"30","author":"D Antoine","year":"2021","unstructured":"Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone. Am J Addict. 2021;30(1):83\u20137.","journal-title":"Am J Addict"},{"issue":"2","key":"305_CR40","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw open. 2020;3(2):e1920622.","journal-title":"JAMA Netw open"},{"key":"305_CR41","first-page":"CD003410","volume":"8","author":"M Ferri","year":"2010","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2010;8:CD003410.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"305_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-016-0127-9","volume":"14","author":"S Boyd","year":"2017","unstructured":"Boyd S, Murray D, MacPherson D. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14(1):1\u201314.","journal-title":"Harm Reduct J"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00305-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:12:19Z","timestamp":1649153539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00305-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00305-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the participant. Ethical approval from the University of British Columbia Research Ethics Board was not required by virtue of the study being a case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}